

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 19, 2025

## HEK-293T-hACE2

RRID:CVCL\_A7UK

Type: Cell Line

### Proper Citation

(BEI\_Resources Cat# NR-52511, RRID:CVCL\_A7UK)

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_A7UK](https://web.expasy.org/cellosaurus/CVCL_A7UK)

**Proper Citation:** (BEI\_Resources Cat# NR-52511, RRID:CVCL\_A7UK)

**Sex:** Female

**Defining Citation:** [PMID:33495308](#)

**Comments:** Characteristics: Expresses ACE2 under the control of the EF1a promoter (BEI\_Resources=NR-52511)., Group: SARS-CoV-2 research cell line.

**Category:** Transformed cell line

**Name:** HEK-293T-hACE2

**Synonyms:** 293T-ACE2

**Cross References:** BEI\_Resources:NR-52511, Wikidata:Q107115255

**ID:** CVCL\_A7UK

**Vendor:** BEI\_Resources

**Catalog Number:** NR-52511

**Record Creation Time:** 20250131T200341+0000

**Record Last Update:** 20250131T201550+0000

### Ratings and Alerts

No rating or validation information has been found for HEK-293T-hACE2.

No alerts have been found for HEK-293T-hACE2.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 34 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Li P, et al. (2024) Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. *mBio*, 15(5), e0075124.

Li P, et al. (2024) Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion. *bioRxiv* : the preprint server for biology.

Cohen AA, et al. (2024) Mosaic sarbecovirus vaccination elicits cross-reactive responses in pre-immunized animals. *bioRxiv* : the preprint server for biology.

Faraone JN, et al. (2024) Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination. *Journal of medical virology*, 96(3), e29520.

Li P, et al. (2024) Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion. *bioRxiv* : the preprint server for biology.

Li P, et al. (2024) Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants. *bioRxiv* : the preprint server for biology.

Qu P, et al. (2024) Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants. *Cell*, 187(3), 585.

Li P, et al. (2024) Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants. *Cell reports*, 43(8), 114520.

Li P, et al. (2024) Immune Evasion, Cell-Cell Fusion, and Spike Stability of the SARS-CoV-2 XEC Variant: Role of Glycosylation Mutations at the N-terminal Domain. *bioRxiv* : the preprint server for biology.

Qu P, et al. (2023) Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants. *mBio*, 14(1), e0317622.

Faraone JN, et al. (2023) Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants. *Cell reports Medicine*, 4(5), 101049.

Subhadra B, et al. (2023) Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2. *Viruses*, 15(6).

Qu P, et al. (2023) Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants. *bioRxiv : the preprint server for biology*.

Qu P, et al. (2023) Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. *Cell reports*, 42(5), 112443.

Faraone JN, et al. (2023) Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3. *Emerging microbes & infections*, 12(2), 2270069.

Qu P, et al. (2023) Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants. *bioRxiv : the preprint server for biology*.

Guerra D, et al. (2023) Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual. *iScience*, 26(10), 108009.

Khatun O, et al. (2023) SARS-CoV-2 ORF6 protein targets TRIM25 for proteasomal degradation to diminish K63-linked RIG-I ubiquitination and type-I interferon induction. *Cellular and molecular life sciences : CMLS*, 80(12), 364.

Korenkov M, et al. (2023) Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants. *Immunity*, 56(12), 2803.

Qu P, et al. (2023) Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. *Cell host & microbe*, 31(1), 9.